Of note, FGFR overexpression and activation were identified as a mechanism of resistance to IGF-1R inhibitors and other targeted drugs in other tumor types, including in a rhabdomyosarcoma model [44] and in lung cancer [45]. Here, IGF1R is linked to lung carcinoma.